PFE

MKT CAP:$154B

Pfizer Inc.

Market Cap

$154B

Healthcare·Drug Manufacturers - General·🇺🇸 United States·NYSE

Healthcare·Drug Mfg.·🇺🇸·NYSE

Stock Price

$26.98+$1.80 (+7.17%)

Apr 24, 2026

Company Details

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under ...

CEO

Albert Bourla

IPO Date

Jun 1, 1972

Website

www.pfizer.com

Key Metrics TTM

Revenue

$65.6B

+17.3% YoY

Net Income

$9.3B

EPS (Diluted)

$1.63

Free Cash Flow

$16.3B

Revenue / Share

$11.54

Gross Margin

69.1%

Operating Margin

25.6%

Net Margin

14.2%

FCF Margin

24.9%

P/S

2.3x

P/E

16.5x

Earnings Reports

Q1 2026

May 5, 2026

PENDING

FY 2025

Feb 26, 2026

$62.6B-1.6%EPS $1.36

Q4 2025

Feb 26, 2026

$17.6BEPS -$0.29

Q3 2025

Nov 4, 2025

$16.7B-5.9%EPS $0.62

Q1 2025

May 5, 2025

$13.7B-7.8%EPS $0.52

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 19	$12.7B	$8.9B	$3.4B
Q1 21	$14.5B	$9.5B	$4.8B
Q3 21	$24.0B	$13.2B	$7.8B
Q1 22	$25.7B	$14.9B	$10.0B
Q2 22	$27.7B	$18.7B	$12.9B
Q3 22	$22.6B	$15.6B	$9.7B
Q4 22	$24.3B	$13.4B	$5.3B
Q1 23	$18.5B	$12.5B	$6.7B
Q2 23	$13.0B	$8.4B	$2.4B
Q3 23	$13.5B	$2.9B	-$3.0B
Q4 23	$14.6B	$6.0B	-$1.3B
Q1 24	$14.9B	$10.5B	$4.6B
Q3 24	$17.7B	$10.8B	$5.0B
Q1 25	$13.7B	$9.8B	$4.6B
Q3 25	$16.7B	$12.5B	$3.5B
Q4 25	$17.6B	$12.3B	$3.7B

Valuation

Quarter	P/S	P/E
Q3 19	3.6x	9.1x
Q1 21	3.8x	9.5x
Q3 21	3.7x	9.2x
Q1 22	3.7x	10.0x
Q2 22	3.2x	9.4x
Q3 22	2.5x	7.2x
Q4 22	2.7x	8.7x
Q1 23	2.5x	8.0x
Q2 23	2.6x	9.6x
Q3 23	2.8x	18.3x
Q4 23	2.8x	78.4x
Q1 24	2.8x	—
Q3 24	2.7x	88.4x
Q1 25	2.4x	20.0x
Q3 25	2.2x	9.6x
Q4 25	2.2x	15.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 19	$4.5B	$3.8B
Q1 21	$4.5B	$4.0B
Q3 21	$10.8B	$10.2B
Q1 22	$6.5B	$5.9B
Q2 22	$8.2B	$7.4B
Q3 22	$6.0B	$5.1B
Q4 22	$8.6B	$7.6B
Q1 23	$1.2B	$74M
Q2 23	-$1.2B	-$2.1B
Q3 23	$3.5B	$2.6B
Q4 23	$5.2B	$4.2B
Q1 24	$1.1B	$386M
Q3 24	$6.7B	$6.1B
Q1 25	$2.3B	$1.8B
Q3 25	$4.6B	$4.0B
Q4 25	$5.3B	$4.5B

Capital Expenditures

Quarter	CapEx
Q3 19	$662M
Q1 21	$554M
Q3 21	$624M
Q1 22	$643M
Q2 22	$751M
Q3 22	$841M
Q4 22	$1.0B
Q1 23	$1.1B
Q2 23	$914M
Q3 23	$810M
Q4 23	$1.0B
Q1 24	$704M
Q3 24	$651M
Q1 25	$564M
Q3 25	$602M
Q4 25	$845M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 19	-5.8%	-1.0%
Q1 21	+9.2%	+3.2%
Q3 21	+83.2%	+88.9%
Q1 22	+93.5%	+72.4%
Q2 22	+118.8%	+58.9%
Q3 22	+56.0%	+33.3%
Q4 22	+1.1%	+16.3%
Q1 23	-28.0%	-24.4%
Q2 23	-53.1%	-28.0%
Q3 23	-40.4%	+27.5%
Q4 23	-40.0%	-16.4%
Q1 24	-19.5%	-12.5%
Q3 24	+36.1%	+19.5%
Q1 25	+1.7%	-44.9%
Q3 25	+14.3%	-17.2%
Q4 25	+18.0%	+34.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 19	$64M	0.5%
Q1 21	$172M	1.2%
Q3 21	$293M	1.2%
Q1 22	$86M	0.3%
Q2 22	$287M	1.0%
Q3 22	$135M	0.6%
Q4 22	$364M	1.5%
Q1 23	$105M	0.6%
Q2 23	$148M	1.1%
Q3 23	$151M	1.1%
Q4 23	$121M	0.8%
Q1 24	$220M	1.5%
Q3 24	$274M	1.5%
Q1 25	$170M	1.2%
Q3 25	$201M	1.2%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q3 19	$2.3B	$3.2B
Q1 21	$2.0B	$2.7B
Q3 21	$2.7B	$2.7B
Q1 22	$2.3B	$2.5B
Q2 22	$2.8B	$2.9B
Q3 22	$2.7B	$3.3B
Q4 22	$3.6B	$4.4B
Q1 23	$2.5B	$3.4B
Q2 23	$2.6B	$3.4B
Q3 23	$2.7B	$3.2B
Q4 23	$2.8B	$4.5B
Q1 24	$2.5B	$3.5B
Q3 24	$2.6B	$3.2B
Q1 25	$2.2B	$3.0B
Q3 25	$3.9B	$3.2B
Q4 25	$3.4B	$3.7B

Revenue Segments

Quarter	Biopharma Segment	Upjohn Segment	Business Innovation Segment
Q3 19	$10.1B	$2.2B	—
Q1 22	$25.3B	—	—
Q2 22	$27.4B	—	—
Q3 22	$22.3B	—	—
Q4 22	$23.9B	—	—
Q1 23	$18.0B	—	$310M
Q2 23	$12.4B	—	$316M
Q3 23	$12.9B	—	$302M
Q4 23	$13.9B	—	$382M
Q1 24	$14.6B	—	$275M
Q3 24	$17.4B	—	—
Q3 25	$16.3B	—	—

Revenue by Geography

Quarter	Developed Europe	Developed Rest Of World	Emerging Markets	United States
Q3 19	$2.1B	$1.6B	$3.1B	$5.8B
Q1 21	$3.0B	$1.1B	$2.8B	$7.6B
Q3 21	$6.2B	$4.5B	$6.3B	$7.1B
Q1 22	$6.1B	$3.3B	$7.4B	$8.9B
Q2 22	$5.5B	$5.0B	$6.0B	$11.2B
Q3 22	$3.1B	$2.4B	$3.3B	$13.9B
Q4 22	$7.3B	$5.1B	$3.4B	$8.5B
Q1 23	$2.8B	$2.5B	$4.5B	$8.5B
Q2 23	$2.4B	$1.3B	$2.8B	$6.2B
Q3 23	$2.0B	$1.1B	$2.4B	$7.8B
Q4 23	$4.4B	$2.9B	$2.3B	$4.6B
Q1 24	—	$3.2B	$2.2B	$9.5B
Q3 24	—	$3.4B	$2.2B	$12.1B
Q3 25	—	$3.7B	$2.3B	$10.7B

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$2.5B	$21.4B	$23.9B
Q2 22	$1.8B	$31.5B	$33.3B
Q3 22	$1.3B	$34.8B	$36.1B
Q4 22	$416M	$22.3B	$22.7B
Q1 23	$2.2B	$17.8B	$20.0B
Q2 23	$2.6B	$42.2B	$44.8B
Q3 23	$3.1B	$41.0B	$44.2B
Q4 23	$2.9B	$9.8B	$12.7B
Q1 24	$719M	$11.2B	$11.9B
Q2 24	$1.1B	$6.0B	$7.1B
Q3 24	$1.1B	$8.9B	$10.0B
Q4 24	$1.0B	$19.4B	$20.5B
Q1 25	$1.4B	$15.9B	$17.3B
Q2 25	$1.6B	$11.6B	$13.2B
Q3 25	$1.3B	$13.6B	$15.0B
Q4 25	$1.1B	$12.5B	$13.6B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 19	5.65B	-0.4%	-5.1%
Q1 21	5.66B	+0.2%	-5.4%
Q3 21	5.72B	+1.1%	-0.4%
Q1 22	5.76B	+0.6%	+1.5%
Q2 22	5.71B	-0.8%	+1.1%
Q3 22	5.72B	+0.1%	+1.0%
Q4 22	5.74B	+0.4%	+0.3%
Q1 23	5.73B	-0.3%	-0.5%
Q2 23	5.71B	-0.2%	+0.0%
Q3 23	5.65B	-1.2%	-1.3%
Q4 23	5.65B	+0.0%	-1.7%
Q1 24	5.70B	+0.9%	-0.5%
Q3 24	5.71B	+0.1%	-0.1%
Q1 25	5.71B	+0.1%	+1.1%
Q3 25	5.71B	+0.1%	+1.2%
Q4 25	5.69B	-0.5%	-0.2%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 19	$137.2K	92K
Q1 21	$184.9K	79K
Q3 21	$306.2K	79K
Q1 22	$324.8K	79K
Q2 22	$351.2K	79K
Q3 22	$286.6K	79K
Q4 22	$292.7K	83K
Q1 23	$222.7K	83K
Q2 23	$156.7K	83K
Q3 23	$162.5K	83K
Q4 23	$165.6K	88K
Q1 24	$169.1K	88K
Q3 24	$201.2K	88K
Q1 25	$169.3K	81K
Q3 25	$205.6K	81K
Q4 25	$234.1K	75K

Revenue / Employee